Punarnava for Health & Longevity - Quick Reference Sheet

Punarnava for Health & Longevity

Created on 10/18/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Punarnava is a traditional Indian herb used for fluid balance, kidney filtration, and blood-vessel health. Human longevity evidence is low to speculative: healthy adults are untested, and mostly multi-ingredient trials show reduced fluid retention, painful urination, urinary protein leakage, and blood pressure without improving filtration. Main hazards are heavy metals in mineral-fortified products, rising uric acid in impaired kidneys, digestive upset, rare rash, and laboratory drug-enzyme inhibition. (Full Review)

Protocol

Standard oral dosing
500–1,000 mg/day standardized extract
Or 1,000–3,000 mg/day root powder or 20–30 mL decoction twice daily
Half-life and split dosing
500–1,000 mg twice or thrice daily
Human half-life is unknown (3–5 hours in rats)
Best time of day
With breakfast and lunch
At least 6 hours before sleep to prevent nighttime urination
Time to effect
Edema and Ascites Reduction
24–72 hours to 1 month
Mild diuresis in 24–72 hours; edema reduction over 1 month
Renal Function and Albuminuria Support
2–8 weeks
24-hour urinary microalbumin reduction in multi-herb trials
Blood Pressure Reduction
2–8 weeks
Systolic and diastolic blood pressure reductions in multi-herb trials

Benefits

Contraindications
  • Severe renal impairment or macroalbuminuria (plasma creatinine >2.5 mg/dL or 24-hour urine albumin >300 mg/24 hours)
  • Severe or uncontrolled hypertension (blood pressure >200/120 mmHg)
  • Decompensated liver disease (hepatocellular failure, hepatic encephalopathy, portal hypertension with ascites, or obstructive jaundice)
  • First-trimester pregnancy, severe gestational anemia, or preeclampsia (hemoglobin <6 g/dL)
  • Children and adolescents under 15 years (for polyherbal hepatic regimens)
  • Hemochromatosis (iron overload disorder) or elevated serum ferritin (for Punarnava Mandura)
Key Interactions
  • CYP2B6, CYP2D6, and CYP3A4 substrates (efavirenz, bupropion) (theoretical)
  • CYP1A2 substrates (theophylline, tizanidine) (theoretical)
  • BCRP/ABCG2 substrates (rosuvastatin, methotrexate) (theoretical)
  • Prescription diuretics and antihypertensives (furosemide, lisinopril) (theoretical)
  • Antidiabetic medications (metformin, insulin) (theoretical)
  • Over-the-counter medications (ibuprofen, senna) (theoretical)
  • Hypotensive, diuretic, and hypoglycemic supplements (berberine, dandelion root) (theoretical)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Gastrointestinal irritation, diarrhea, and vomiting; serum uric acid elevation in impaired renal function; heavy metal contamination in herbo-mineral formulations; cutaneous hypersensitivity reactions
  • Speculative: Cytochrome P450 and BCRP efflux transporter interactions; electrolyte imbalance and hypotension

Monitoring

Marker Target Why
24-Hour Urine Microalbumin <30 mg/24 hours Quantifies reduction in urinary albumin leakage
Seated Blood Pressure No established target; track reduction from baseline and absence of symptomatic hypotension Tracks antihypertensive response and screens for hypotension
Serum Creatinine & eGFR Creatinine 0.6–1.2 mg/dL; eGFR ≥90 mL/min/1.73 m² Detects volume-depletion renal strain and verifies trial cutoff (≤2.5 mg/dL)
Serum Uric Acid 3.5–7.2 mg/dL Detects diuretic-induced hyperuricemia versus urate lowering
Serum Potassium & Sodium Potassium 3.5–5.0 mmol/L; Sodium 135–145 mmol/L Detects diuretic-associated hypokalemia or hyponatremia
ALT, AST & Total Bilirubin ALT 10–40 IU/L; AST 5–40 IU/L; Bilirubin 0.10–1.20 mg/dL Tracks hepatic recovery and screens for herb-induced liver injury
Whole-Blood Lead, Mercury & Arsenic Lead <3.5 µg/dL; Mercury <5.0 µg/L; Arsenic <10 µg/L Screens for toxic metal bioaccumulation from Ayurvedic products
Hemoglobin, Serum Iron & Ferritin Hemoglobin 12.0–17.5 g/dL; Iron 60–170 µg/dL; Ferritin 30–300 ng/mL Tracks anemia correction and prevents iron overload

Cadence: Baseline; seated blood pressure and morning body weight weekly during month 1; renal function, serum electrolytes, uric acid, liver enzymes, and urinary albumin at 4 and 8–12 weeks; heavy-metal screening at 8–12 weeks for uncertified powders.

Qualitative Assessment

  • Peripheral fluid retention: Reduction in ankle, pedal, or periorbital puffiness and stable morning body weight.
  • Urinary pattern: Daytime diuresis without nocturnal sleep disruption.
  • Orthostatic tolerance and digestion: Absence of standing lightheadedness, abdominal cramping, or loose stools.